Anxiety disorders in outpatients with schizophrenia: prevalence and impact on the subjective quality of life

Braga, Raphael J.; Mendlowicz, Mauro V.; Marrocos, Rogério Paysano; Figueira, Ivan

doi:10.1016/j.jpsychires.2004.09.003

Cited by 141 publications

(98 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This agrees with what was reported in a previous study which found significantly higher scores in global scale, work subscale, and social life subscale of the Sheehan Disability Scale in schizophrenia subjects with comorbid anxiety 17,11,27 . This is also in agreement with other studies that found that co-morbid anxiety in schizophrenia was associated with significantly lower level of function 28,29 .…”

supporting

confidence: 93%

“…Differences in the rates of compulsive disorder 13,14,23,25,26 , phobic anxiety disorder 8 and panic disorder 11,23 reported elsewhere and rates revealed in this study may be due to methodological differences.…”

contrasting

confidence: 58%

“…Other studies reported specific prevalence of social phobia (17%), obsessive compulsive disorder (15.1%), generalized anxiety disorder (9.4%), panic disorder (5.7%), specific phobia (5.7%) and 1.9% for agoraphobia 11 . A large community-based, controlled, prospective study in in newly diagnosed patients with psychotic disorders found 10 to 20 -percent prevalence rates for co-morbid obsessive compulsive disorder 12 …”

Section: Introductionmentioning

confidence: 96%

“…Other studies of anxiety disorder in schizophrenia reported a higher anxiety rate of 43% 23 and 41.5% 22 . These higher rates may be explained by the use of in-patients who may report higher rates of anxiety than the out-patients 23 and the measurement of lifetime rates instead of current rate of anxiety disorder 11 .…”

mentioning

confidence: 99%

See 3 more Smart Citations

Co-morbid anxiety disorders in patients with schizophrenia in a tertiary institution in South East Nigeria: prevalence and correlates.

Aguocha

Uwakwe

et al. 2015

Afr H. Sci.

View full text Add to dashboard Cite

Background: Anxiety disorders occur commonly in schizophrenia but are often overlooked by psychiatrists. Their presence may compound the challenges faced by these patients and may contribute to poor outcome. Objectives: The purpose of this study was to determine the prevalence of anxiety disorders among the participants with schizophrenia, and the association between this co-morbidity and disability. Method: A total of 367 participants were recruited from the out-patient department of Federal neuropsychiatric hospital Enugu, Nigeria. Socio-demographic questionnaire, schedules for clinical assessment in neuropsychiatry, positive and negative syndrome scale and the 12-item version of the World Health Organization disability assessment schedule were administered. Results: A total of 189 females (51.5%) and 178 (48.5%) males were studied. A lifetime prevalence of 12.3% was reported for anxiety disorder. Anxiety disorder was more likely in females (κ²=4.93, p<0.03). Specific prevalence for anxiety disorder in schizophrenia was generalized anxiety disorder 6.3%, obsessive compulsive disorder 3.3%, and phobic anxiety disorder 2.7%. Anxiety disorder was associated with increased disability (t=3.50, p<0.001) and psychopathology (t=3.40, p<0.001) among the participants studied. Phobias were associated with prescription of low doses of antipsychotics (κ²=4.08, p<0.04). There was a low rate of identification of anxiety disorder in routine clinical practice (k=0.08, p<0.001). Conclusion: Co-morbid anxiety disorders are common in schizophrenia and they are associated with increased disability and psychopathology. The results emphasize the need to screen for anxiety disorders in patients with schizophrenia.

show abstract

supporting

confidence: 93%

contrasting

confidence: 58%

Section: Introductionmentioning

confidence: 96%

mentioning

confidence: 99%

See 2 more Smart Citations

Co-morbid anxiety disorders in patients with schizophrenia in a tertiary institution in South East Nigeria: prevalence and correlates.

Aguocha

Uwakwe

et al. 2015

Afr H. Sci.

View full text Add to dashboard Cite

show abstract

“…Anxiety disorders, the most common psychiatric conditions, affect approximately one out of five people worldwide, are highly co-morbid with other major psychiatric diseases (Achim et al, 2011), and pose an additional burden to patients with a negative impact on recovery and disease outcome (Braga et al, 2005). Owing to the lack of indepth molecular understanding of anxiety pathobiology, current therapeutic approaches are mainly symptom-rather than mechanism-driven with a third of patients being unresponsive to anxiolytic treatment (Bystritsky, 2006).…”

Section: Introductionmentioning

confidence: 99%

Selective Mitochondrial Targeting Exerts Anxiolytic Effects In Vivo

Nussbaumer

Asara

Teplytska

et al. 2015

Neuropsychopharmacol

View full text Add to dashboard Cite

Current treatment strategies for anxiety disorders are predominantly symptom-based. However, a third of anxiety patients remain unresponsive to anxiolytics highlighting the need for more effective, mechanism-based therapeutic approaches. We have previously compared high vs low anxiety mice and identified changes in mitochondrial pathways, including oxidative phosphorylation and oxidative stress. In this work, we show that selective pharmacological targeting of these mitochondrial pathways exerts anxiolytic effects in vivo. We treated high anxiety-related behavior (HAB) mice with MitoQ, an antioxidant that selectively targets mitochondria. MitoQ administration resulted in decreased anxiety-related behavior in HAB mice. This anxiolytic effect was specific for high anxiety as MitoQ treatment did not affect the anxiety phenotype of C57BL/6N and DBA/2J mouse strains. We furthermore investigated the molecular underpinnings of the MitoQ-driven anxiolytic effect and found that MitoQ treatment alters the brain metabolome and that the response to MitoQ treatment is characterized by distinct molecular signatures. These results indicate that a mechanism-driven approach based on selective mitochondrial targeting has the potential to attenuate the high anxiety phenotype in vivo, thus paving the way for translational implementation as longterm MitoQ administration is well-tolerated with no reported side effects in mice and humans.

show abstract

Schizophrenia Spectrum and Other Psychotic Disorders

2018

Adult Psychopathology and Diagnosis, Eighth Edition

View full text Add to dashboard Cite

Anxiety disorders in outpatients with schizophrenia: prevalence and impact on the subjective quality of life

Cited by 141 publications

References 18 publications

Co-morbid anxiety disorders in patients with schizophrenia in a tertiary institution in South East Nigeria: prevalence and correlates.

Co-morbid anxiety disorders in patients with schizophrenia in a tertiary institution in South East Nigeria: prevalence and correlates.

Selective Mitochondrial Targeting Exerts Anxiolytic Effects In Vivo

Schizophrenia Spectrum and Other Psychotic Disorders

Contact Info

Product

Resources

About